UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of clinical oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3651 - 3658
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2854 - 2860
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Otorhinolaryngology. Stomatology | Otorhinolaryngology (head neck, general aspects and miscellaneous) | Tumors | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Induction Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Cisplatin - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Taxoids - adverse effects | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 394 - 401
Burkitt leukaemia | children | chemotherapy | rituximab | Burkitt lymphoma | Rituximab | Chemotherapy | Children | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Index Medicus | Burkitt Leukaemia | Burkitt Lymphoma | adolescents
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2019, Volume 381, Issue 18, pp. 1728 - 1740
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | fms-Like Tyrosine Kinase 3 - genetics | Liver - drug effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Administration, Oral | Remission Induction | Leukemia, Myeloid, Acute - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Survival Analysis | Aged | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Leukemia, Myeloid, Acute - genetics | Tyrosine | Thrombocytopenia | Laboratories | Myeloid leukemia | Survival | Chemotherapy | Medical prognosis | Death | Remission | Flt3 protein | Acute myeloid leukemia | Protein-tyrosine kinase | Neutropenia | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Pediatric neurology, ISSN 0887-8994, 2015, Volume 53, Issue 1, pp. 31 - 46
Pediatrics | Neurology | Children's Oncology Group | infant brain tumor | stem-cell support | high-dose chemotherapy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Cyclophosphamide - administration & dosage | Thiotepa - administration & dosage | Humans | Child, Preschool | Induction Chemotherapy | Infant | Male | Consolidation Chemotherapy | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Cisplatin - administration & dosage | Feasibility Studies | Carboplatin - adverse effects | Antineoplastic Agents - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Etoposide - adverse effects | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy - adverse effects | Pilot Projects | Brain Neoplasms - therapy | Vincristine - therapeutic use | Cisplatin - adverse effects | Vincristine - adverse effects | Combined Modality Therapy - methods | Thiotepa - adverse effects | Brain | Chemotherapy | Research | Brain tumors | Cancer | Index Medicus | Young children | brain tumors | Children’s Oncology Group | intensive chemotherapy
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2014, Volume 32, Issue 25, pp. 2735 - 2743
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Carcinoma, Squamous Cell - radiotherapy | Chemoradiotherapy | Cisplatin - administration & dosage | Squamous Cell Carcinoma of Head and Neck | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Taxoids - adverse effects | Docetaxel | Head and Neck Neoplasms - drug therapy | Hydroxyurea - administration & dosage | Survival Rate | Head and Neck Neoplasms - radiotherapy | Taxoids - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Hydroxyurea - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Index Medicus | Brazil | ORIGINAL REPORTS | Hnc6
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Hematology | Science & Technology | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Infections - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Bevacizumab | Patient Selection | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Neoplasm Invasiveness - pathology | Adult | Remission Induction - methods | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Retreatment | Maximum Tolerated Dose | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Relapse | Chemotherapy | Breast cancer | Metastasis | Angiogenesis inhibitors | Diseases | Cancer | Index Medicus
Journal Article
Supportive care in cancer, ISSN 0941-4355, 11/2020, Volume 28, Issue 11, pp. 5335 - 5342
Health Care Sciences & Services | Oncology | Rehabilitation | Life Sciences & Biomedicine | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Antiemetics - therapeutic use | Placebos | Adult | Female | Olanzapine - adverse effects | Drug Therapy, Combination | Vomiting - prevention & control | Aprepitant - therapeutic use | Olanzapine - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Ondansetron - administration & dosage | Treatment Outcome | Emetics - administration & dosage | Induction Chemotherapy - adverse effects | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Emetics - adverse effects | Cisplatin - adverse effects | Quality of Life | Aged | Ondansetron - adverse effects | Neoplasms - pathology | Doxorubicin - adverse effects | Chemoprevention - methods | Prevention | Aprepitant | Chemotherapy | Anthracyclines | Cyclophosphamide | Olanzapine | Dexamethasone | Nausea | Cancer | Palonosetron | Index Medicus
Journal Article